Developing Innovative Therapeutics

Our Company

Inflection Biosciences is developing small molecule therapeutics for the treatment of cancer, autoimmune and inflammatory disease. The pipeline comprises of IBL-101, an oral, pan-PIM kinase inhibitor in development for autoimmune and inflammatory disease, IBL-202, selected from a series of unique dual mechanism kinase inhibitors and AUM302 (formerly IBL-302), partnered with AUM Biosciences.

What We Do

Pipeline

Partnerships

NEWS

Inflection Biosciences

May 30

Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence

ESCHBORN, Germany, May 30, 2022 Innoplexus, a global leader in AI-based drug discovery and development, and Inflection Biosciences Ltd.,...

Inflection Biosciences

May 27

Inflection Biosciences Announces Expansion of Research into Autoimmune and Inflammatory Disease

Expands Advisory Panel with Immunology and Rheumatology Expertise Dublin, Ireland, May 27, 2022 Inflection Biosciences Ltd, a company...

Inflection Biosciences

Nov 11, 2021

Inflection Biosciences Announces Publication on Discovery of AUM302 in ACS Medicinal Chemistry

Dublin, Ireland, November 10, 2021 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer,...